Inventor · disambiguated record
Catherine Deloche
Also filed as: DELOCHE CATHERINE
8 granted patents·9 pending applications·13 citations·filing 2010–2022
79Inventor score
Top patents by PatentIndex Score
17 records- 0178US9150618B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesCOMBETTE JEAN-MARC·Filed 2010·Granted Oct 6, 2015·8 cites·9 claims
- 0276US10596223B2JNK inhibitor molecules for treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2016·Granted Mar 24, 2020·1 cites·5 claims
- 0370US8747856B2Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseasesABADIE CLAIRE·Filed 2010·Granted Jun 10, 2014·4 cites·5 claims
- 0469US2022280591A1Use For JNK Inhibitor Molecules For Treatment Of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2022·Application pending·0 cites
- 0559US2015133393A1Novel JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2012·Application pending·0 cites
- 0659US2020206301A1JNK Inhibitor Molecules For Treatment Of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2020·Application pending·0 cites
- 0756US11779628B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2015·Granted Oct 10, 2023·0 cites·1 claims
- 0855US10967038B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesXIGEN INFLAMMATION LTD·Filed 2018·Granted Apr 6, 2021·0 cites·2 claims
- 0954US2016115200A1New Use for JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2014·Application pending·0 cites
- 1049US10624948B2Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2014·Granted Apr 21, 2020·0 cites·8 claims
- 1145US11331364B2Use for JNK inhibitor molecules for treatment of various diseasesXIGEN INFLAMMATION LTD·Filed 2019·Granted May 17, 2022·0 cites·17 claims
- 1245US2014309400A1Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye SyndromeXIGEN INFLAMMATION LTD·Filed 2012·Application pending·0 cites
- 1344US2017128516A1Use for JNK Inhibitor Molecules for Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 1443US2016089413A1Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 1538US10098925B2Protein SLURP-1 for use in the treatment of ocular diseasesBRIGHTPULSE HOLDING LTD·Filed 2013·Granted Oct 16, 2018·0 cites·14 claims
- 1638US2017137481A1Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various DiseasesXIGEN INFLAMMATION LTD·Filed 2015·Application pending·0 cites
- 1736US2018170983A1New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive ImpairmentXIGEN INFLAMMATION LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Catherine Deloche files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →